CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
EpiEndo is developing Bronchomycn, a new drug for treating chronic obstructive pulmonary disease (COPD) by enhancing airway epithelial barrier function. This innovative compound, derived from azithromycin, aims to reduce lung permeability to harmful agents, addressing a significant health issue affecting millions world…
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity.According to the World Health Organization 64 million people suffered COPD in 2004.
The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths.
As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.…
EpiEndo Pharmaceuticals ehf
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
